Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SafiledCriticalNicox Sa
Publication of AR080274A1publicationCriticalpatent/AR080274A1/en
C07C203/04—Esters of nitric acid having nitrate groups bound to acyclic carbon atoms
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Novedoso derivado de naproxeno que libera oxido nítrico y su uso para el tratamiento de enfermedades asociadas con dolor e inflamacion. Este derivado de naproxeno que libera no muestra una seguridad gastrointestinal sorprendentemente mejorada y posee beneficios como cardioprotector. Reivindicacion 1: El compuesto [2-(6-metoxinaftalen-2-iI)propanoato de (S)-((S)-5,6-bis(nitrooxi)hexilo)], caracterizado porque tiene la formula (1). Reivindicacion 8: Una composicion caracterizada porque comprende el compuesto de la reivindicacion 1 y por lo menos otro agente terapéutico que se selecciona entre: inhibidores de 5-lipooxigenasa (5-LO), antagonistas del receptor de leucotrieno B4 (LTB4), inhibidores de la hidrolasa de leucotrieno A4 (LTA4, agonistas de 5-HT, inhibidores de HMG-CoA, antagonistas del receptor H2, agentes antineoplásticos, agentes antiplaquetas, inhibidores de trombina, inhibidores de tromboxano, descongestivos, diuréticos, antihistamínicos sedantes o no sedantes, inhibidores de la oxido nítrico sintasa inducible, opiodes, analgésicos, inhibidores de Helicobacter pylori, inhibidores de isoprostano, y mezclas de dos o más de los mismos.Novel naproxen derivative that releases nitric oxide and its use for the treatment of diseases associated with pain and inflammation. This naproxen derivative that it releases does not show surprisingly improved gastrointestinal safety and has benefits as a cardioprotective. Claim 1: The compound (2- (6-methoxynaphthalen-2-iI) propanoate of (S) - ((S) -5,6-bis (nitrooxy) hexyl)], characterized in that it has the formula (1). Claim 8: A composition characterized in that it comprises the compound of claim 1 and at least one other therapeutic agent that is selected from: 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 receptor antagonists (LTB4), inhibitors of the leukotriene A4 hydrolase (LTA4, 5-HT agonists, HMG-CoA inhibitors, H2 receptor antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedative or non-sedating antihistamines, inhibitors inducible nitric oxide synthase, opiodes, analgesics, Helicobacter pylori inhibitors, isoprostane inhibitors, and mixtures of two or more thereof.
ARP100102740A2009-07-282010-07-28
NAPROXENE THAT RELEASES NITRIC OXIDE AND PHARMACEUTICAL COMPOSITION
AR080274A1
(en)
Compounds derived from substituted carboxyamide heterocycles, ar antagonist; pharmaceutical composition comprising them; and use in the treatment of prostate cancer.
HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
Pharmaceutical composition comprising acetaminophen and a complex tramadol material, which exhibits a sustained and coordinated release through a sustained release and an immediate release layer; method of preparation; and the use of a complex material of tramadol and acetaminophen to prepare a medication for the treatment of pain.
Composition and preparation process of a solvent free biocide comprising at least one water insoluble biocide and a water soluble carrier material in nano-dispersed form with a peak diameter under 1000 nm.
Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
COMPOUNDS DERIVED FROM PIRROLO PIRIDINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE FOR THE TREATMENT OF THE DISEASE OF ALZHEIMER, PARKINSON, CANCER, AMONG OTHER ILLNESSES.
Compounds derived from 3-benzoisoxazole-piperidine; pharmaceutical composition comprising said compounds; and its use for the treatment and / or prevention of cognitive disorders, drug addiction, depression, anxiety, among others.
Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others.
Pharmaceutical composition comprising micronized progesterone and type II safflower oil; and use for the treatment of a condition related to insufficient progesterone secretion.
COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
Immediate release oral pharmaceutical formulation comprising nalbuphine or a salt thereof, and at least a hydrophilic granulation support, a hydrophilic binder and a lubricant, useful for the treatment of pain and dependence on opioids.
Aqueous injectable composition of diclofenac in a solution of diethylene glycol monoethyl ether and water; Preparation method; and use in the treatment or prevention of pain and / or inflammatory conditions such as headache, sore throat, among others.
Method to treat overweight or obesity that includes administering naltrexone and bupropion; method to increase the bioavailability of naltrexone and bupropion in a combination therapy; use of naltrexone and bupropion to treat overweight or obesity and increase the bioavailability of these drugs; pharmaceutical composition